Proton Beam Radiotherapy for Breast Cancer

Phase-Based Progress Estimates
Breast Cancer+1 More
Proton Beam Radiotherapy - Radiation
What conditions do you have?

Study Summary

This trial is testing whether proton therapy is an effective and safe treatment for early stage breast cancer.

Eligible Conditions
  • Breast Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 5 years

5 years
Disease Free Survival
Rate of breast recurrence of low versus intermediate risk patients
Rate of recurrence in the breast
Side-effects related to treatment

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Partial Breast Proton Therapy
1 of 1
Experimental Treatment

150 Total Participants · 1 Treatment Group

Primary Treatment: Proton Beam Radiotherapy · No Placebo Group · N/A

Partial Breast Proton Therapy
Experimental Group · 1 Intervention: Proton Beam Radiotherapy · Intervention Types: Radiation
First Studied
Drug Approval Stage
How many patients have taken this drug
Proton Beam Radiotherapy

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Who is running the clinical trial?

Loma Linda UniversityLead Sponsor
285 Previous Clinical Trials
257,885 Total Patients Enrolled
3 Trials studying Breast Cancer
96,074 Patients Enrolled for Breast Cancer
David A Bush, MDPrincipal InvestigatorRadiation Medicine - Loma Linda University Medical Center
1 Previous Clinical Trials
76 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Female Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a primary tumor that is 3 centimeters or less in size.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 16th, 2021

Last Reviewed: October 24th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.